Clinical characteristics affecting weight loss in an East Asian population receiving semaglutide: A STEP 6 subgroup analysis

Jan 17, 2025Obesity research & clinical practice

Clinical factors linked to weight loss in East Asian people taking semaglutide

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

The estimated mean change in body weight was -9.40% to -16.42% for semaglutide 2.4 mg across all subgroups.

Both doses of semaglutide showed significant treatment differences compared to placebo.
Significant interactions based on sex were observed for semaglutide 1.7 mg and 2.4 mg versus placebo.
Interactions related to the presence of type 2 diabetes and dyslipidemia at baseline were significant for semaglutide 2.4 mg compared to placebo.
Results suggest semaglutide may be effective for weight reduction in individuals with various weight-related health issues.

AI simplified

OBJECTIVE: To explore the effects of semaglutide versus placebo on body weight (BW) by subgroups of baseline characteristics.

METHODS: In STEP 6, Japanese and Korean adults with overweight or obesity were randomized to subcutaneous semaglutide 2.4 mg, semaglutide 1.7 mg, or placebo for 68 weeks. A subset of Japanese participants with type 2 diabetes (T2D) was also included. In this post-hoc analysis, change from baseline in BW (%) was assessed by subgroups of baseline characteristics including baseline BW, body mass index, age, sex, glycemic status, dyslipidemia, and hypertension.

RESULTS: Of 401 participants (148 female and 253 male) included, the estimated mean change in BW was clinically relevant across all subgroups for semaglutide 2.4 mg, ranging from -9.40 % to -16.42 %. Estimated treatment differences also favored both semaglutide doses versus placebo. Significant treatment-by-subgroup interactions were observed for sex with semaglutide 1.7 mg and 2.4 mg versus placebo at week 68 (p = 0.0008 and p = 0.0005, respectively). Significant treatment-by-subgroup interactions were also observed for presence of T2D and dyslipidemia at baseline, for semaglutide 2.4 mg versus placebo only (p = 0.0381 and p = 0.0181, respectively).

CONCLUSIONS: Semaglutide reduces BW in a wide demographic of people with a range of weight-related comorbidities in an East Asian population.

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

Clinical characteristics affecting weight loss in an East Asian population receiving semaglutide: A STEP 6 subgroup analysis

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief